



ASX / Media Release

21 February 2014

CIRCADIAN APPOINTS CEO AND MANAGING DIRECTOR

The Board of Directors of Circadian Technologies Limited (ASX:CIR) is pleased to announce the appointment of Dr Megan Baldwin to the position of Chief Executive Officer and Managing Director, effective February 24 2014.

Dr Baldwin brings over 18 years of experience focussing on angiogenesis and therapeutic strategies for cancer and ophthalmic indications.

Dr Baldwin joined Circadian in 2008 and since then has held various positions, including Head of Preclinical R&D and Chief Executive Officer of Opthea Pty Ltd, the 100% owned subsidiary of Circadian, developing OPT-302 (formerly VGX-300) for the treatment of wet age-related macular degeneration.

As Opthea CEO, Dr Baldwin led the capital management, investor engagement and advancement of Opthea's program for eye disease. Prior to that, Dr. Baldwin held research and commercial roles at Roche (formerly Genentech) in San Francisco. Dr. Baldwin completed her PhD in medicine at the Ludwig Institute for Cancer Research affiliated with the University of Melbourne.

The Chairman of Circadian, Ms Dominique Fisher, said: "Megan is well credentialed to lead Circadian. Her knowledge of Circadian's technology and business, together with her experience in biotechnology drug development and engagement with the investment community through her leadership of Opthea make her the ideal appointment."

Coinciding with this appointment, Ms Dominique Fisher will resume her role as Non-Executive Director and Chairman.

In accordance with ASX listing rule 3.16.4, the material terms of Ms Baldwin's employment as CEO of Circadian Technologies will be disclosed following finalisation of the contract.

Appendix 3X, Initial Director's Interest Notice, is attached to this announcement.

Media Enquiries

David Symons
(02) 8306 4244

About Circadian Technologies Limited

Circadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are primarily focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for 'back of the eye' disease such as wet age-related macular degeneration (wet AMD). Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.

Suite 0403 Level 4 650 Chapel Street South Yarra Victoria 3141 Australia

T +61 (3) 9826 0399 F +61 (3) 9824 0083 www.circadian.com.au

ABN 32 006 340 567

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	CIRCADIAN TECHNOLOGIES LIMITED
ABN	32 006 340 567

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Megan Baldwin
Date of appointment	24 February 2014

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Number & class of securities	
10,674	Fully paid ordinary shares
200,000	Employee conditional performance rights (unlisted securities - CIRAM)
	Exercise price = \$0.00,
	Expiry date = 31/03/2015

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest. NIL	Number & class of Securities NIL
---	--

+ See chapter 19 for defined terms.

Part 3 – Director's interests in contracts

Detail of contract	NIL
Nature of interest	NIL
Name of registered holder (if issued securities)	NIL
No. and class of securities to which interest relates	NIL

+ See chapter 19 for defined terms.